2.0(top 20%)
impact factor
5.7K(top 5%)
papers
156.7K(top 5%)
citations
121(top 5%)
h-index
2.1(top 20%)
impact factor
6.4K
all documents
164.2K
doc citations
171(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelinesLupus2003757
2Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burdenLupus2006665
3Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid AntibodiesLupus2011467
4Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosusLupus2000438
5Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodiesLupus2000402
6Mechanisms of action of mycophenolate mofetilLupus2005366
7Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled studyLupus2001364
8Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosusLupus2006351
9Sex hormones influence on the immune system: basic and clinical aspects in autoimmunityLupus2004335
10Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patientsLupus2007335
11Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosisLupus2002315
12Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case–control study within LUMINA, a multiethnic US cohort (LUMINA LVII)Lupus2008312
13Cardiac involvement in systemic lupus erythematosusLupus2005305
14Systemic lupus erythematosus in three ethnic groups: III A comparison of characteristics early in the natural history of the LUMINA cohortLupus1999291
15Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategiesLupus2013274
16Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 casesLupus2009273
17Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activityLupus1995267
18A Phospholipid-β2-Glycoprotein I Complex Is an Antigen for Anticardiolipin Antibodies Occurring in Autoimmune Disease But Not with InfectionLupus1992265
19The innate immune system in SLE: type I interferons and dendritic cellsLupus2008262
20Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—A meta-analysisLupus1997259
21Review: Neuropsychiatric involvement in pediatric systemic lupus erythematosusLupus2007259
22Rationale for interleukin-6 blockade in systemic lupus erythematosusLupus2004253
23A Long-Term Study of Hydroxychloroquine Withdrawal on Exacerbations in Systemic Lupus ErythematosusLupus1998250
24Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLELupus2013246
25Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosusLupus2001244
26Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodiesLupus1997241
27Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year studyLupus2006231
28Adjuvants and autoimmunityLupus2009228
29A review of health related quality of life in systemic lupus erythematosusLupus2006226
30Classification and definition of major flares in SLE clinical trialsLupus1999220
31Vasculitis in systemic lupus erythematosusLupus1997217
32Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysisLupus2016214
33Presence of cutaneous interferon-a producing cells in patients with systemic lupus erythematosusLupus2001209
34Validation of a systemic lupus activity questionnaire (SLAQ) for population studiesLupus2003209
35The nature and outcome of infection in systemic lupus erythematosusLupus2002205
36Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosisLupus1996202
37Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patientsLupus1998201
38The interferon-α signature of systemic lupus erythematosusLupus2010201
39Cigarette smoking and autoimmune disease: what can we learn from epidemiology?Lupus2006199
40Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus CohortLupus2000197
41High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosusLupus1998194
42Current causes of death in systemic lupus erythematosus in Europe, 2000—2004: relation to disease activity and damage accrualLupus2007189
43Apoptosis in the pathogenesis of systemic lupus erythematosusLupus2008189
44Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United StatesLupus2002187
45Prognostic determinants in lupus nephritis: a long-term clinicopathologic studyLupus1995186
46Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosisLupus1998186
47Ethnic and geographical differences in systemic lupus erythematosus: an overviewLupus2006186
48Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapyLupus2000185
49The blood-brain barrier in systemic lupus erythematosusLupus2003185
50Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisionsLupus2010185